(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.13%) $79.10
(0.31%) $1.938
(1.00%) $2 334.00
(1.04%) $27.03
(1.25%) $966.80
(0.03%) $0.933
(-0.07%) $11.02
(-0.07%) $0.798
(0.06%) $93.51
Live Chart Being Loaded With Signals
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China...
Stats | |
---|---|
本日の出来高 | 1.10M |
平均出来高 | 766 851 |
時価総額 | 4.68B |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0.300 ( 2023-06-08 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 5.52 |
ATR14 | HKD0.00700 (0.12%) |
ボリューム 相関
Consun Pharmaceutical 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Consun Pharmaceutical 相関 - 通貨/商品
Consun Pharmaceutical 財務諸表
Annual | 2023 |
収益: | HKD2.59B |
総利益: | HKD1.92B (74.19 %) |
EPS: | HKD0.980 |
FY | 2023 |
収益: | HKD2.59B |
総利益: | HKD1.92B (74.19 %) |
EPS: | HKD0.980 |
FY | 2022 |
収益: | HKD2.34B |
総利益: | HKD1.76B (75.35 %) |
EPS: | HKD0.860 |
FY | 2021 |
収益: | HKD2.04B |
総利益: | HKD1.53B (74.70 %) |
EPS: | HKD0.740 |
Financial Reports:
No articles found.
Consun Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.300 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0480 | 2014-09-25 |
Last Dividend | HKD0.300 | 2023-06-08 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 19 | -- |
Total Paid Out | HKD2.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.58 | -- |
Div. Sustainability Score | 9.21 | |
Div.Growth Potential Score | 6.75 | |
Div. Directional Score | 7.98 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2318.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
1286.HK | Ex Dividend Knight | 2023-08-21 | Semi-Annually | 0 | 0.00% | |
0347.HK | No Dividend Player | 2023-06-01 | Sporadic | 0 | 0.00% | |
6099.HK | Ex Dividend Junior | 2023-07-14 | Annually | 0 | 0.00% | |
1848.HK | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
0874.HK | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
0023.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
2660.HK | Ex Dividend Knight | 2023-06-30 | Annually | 0 | 0.00% | |
1425.HK | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
0512.HK | Ex Dividend Knight | 2023-06-09 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.303 | 1.500 | 3.94 | 5.91 | [0 - 0.5] |
returnOnAssetsTTM | 0.142 | 1.200 | 5.25 | 6.30 | [0 - 0.3] |
returnOnEquityTTM | 0.227 | 1.500 | 8.59 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.265 | -1.000 | 7.35 | -7.35 | [0 - 1] |
currentRatioTTM | 2.86 | 0.800 | 0.692 | 0.554 | [1 - 3] |
quickRatioTTM | 2.57 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.838 | 1.500 | 0.898 | 1.347 | [0.2 - 2] |
debtRatioTTM | 0.0921 | -1.500 | 8.46 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.316 | 2.00 | 9.89 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.295 | 2.00 | 9.85 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.140 | -1.500 | 9.44 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.968 | 0.968 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.319 | 1.000 | 5.62 | 5.62 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.501 | 1.000 | 8.33 | 8.33 | [0.2 - 2] |
assetTurnoverTTM | 0.470 | 0.800 | -0.198 | -0.159 | [0.5 - 2] |
Total Score | 9.21 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.44 | 1.000 | 9.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.227 | 2.50 | 9.10 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.295 | 2.00 | 9.90 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.49 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.316 | 2.00 | 9.89 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.265 | 1.500 | 7.35 | -7.35 | [0 - 1] |
pegRatioTTM | 1.199 | 1.500 | 5.34 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0981 | 1.000 | -0.0486 | 0 | [0.1 - 0.5] |
Total Score | 6.75 |
Consun Pharmaceutical
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。